| Rina De Guzman Zuniga, MD | |
|
141 Route 70 E Ste E, Marlton, NJ 08053-1855 | |
| (856) 985-7373 | |
| (856) 985-9611 |
| Full Name | Rina De Guzman Zuniga |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 19 Years |
| Location | 141 Route 70 E Ste E, Marlton, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043565179 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 25MA09699400 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bayada Home Health Care, Inc | Cherry hill, NJ | Home health agency |
| Virtua Home Care At West Jersey | Mount laurel, NJ | Home health agency |
| Virtua West Jersey Hospitals | Voorhees, NJ | Hospital |
| Virtua Our Lady Of Lourdes Hospital | Camden, NJ | Hospital |
| Virtua Memorial Hospital Of Burlington County | Mount holly, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Virtua Medical Group, Pa | 9830222397 | 1226 |
News Archive
Most healthy cells rely on a complicated process to produce the fuel ATP. Knowing how ATP is produced by the cell's energy storehouse - the mitochondria - is important for understanding a cell's normal state, as well as what happens when things go wrong, for example in cancer, cardiovascular disease, neurodegeneration, and many rare disorders of the mitochondria.
In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers from The University of Texas MD Anderson Cancer Center's Therapeutics Discovery division and Ipsen Biopharmaceuticals reported the preclinical discovery and early-stage clinical development of this novel drug. IPN60090, now under investigation in a Phase I trial, may hold benefit for certain patients with lung and ovarian cancers.
BIND Biosciences, Inc. (BIND), a privately held biopharmaceutical company developing best in class therapeutics based on its proprietary targeted nanotechnology platform, announced today that it has secured a $12.4 Million Series C-1 financing. This financing included all of BIND's current investors (including Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension and DHK Investments) as well as a new venture investor, Endeavour Vision, and private investors.
Researchers at the University of Toronto and Unity Health Toronto have demonstrated that repeated listening to personally meaningful music induces beneficial brain plasticity in patients with mild cognitive impairment or early Alzheimer's disease.
› Verified 8 days ago
| Entity Name | Virtua Medical Group, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649226515 PECOS PAC ID: 9830222397 Enrollment ID: O20100804000338 |
News Archive
Most healthy cells rely on a complicated process to produce the fuel ATP. Knowing how ATP is produced by the cell's energy storehouse - the mitochondria - is important for understanding a cell's normal state, as well as what happens when things go wrong, for example in cancer, cardiovascular disease, neurodegeneration, and many rare disorders of the mitochondria.
In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers from The University of Texas MD Anderson Cancer Center's Therapeutics Discovery division and Ipsen Biopharmaceuticals reported the preclinical discovery and early-stage clinical development of this novel drug. IPN60090, now under investigation in a Phase I trial, may hold benefit for certain patients with lung and ovarian cancers.
BIND Biosciences, Inc. (BIND), a privately held biopharmaceutical company developing best in class therapeutics based on its proprietary targeted nanotechnology platform, announced today that it has secured a $12.4 Million Series C-1 financing. This financing included all of BIND's current investors (including Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension and DHK Investments) as well as a new venture investor, Endeavour Vision, and private investors.
Researchers at the University of Toronto and Unity Health Toronto have demonstrated that repeated listening to personally meaningful music induces beneficial brain plasticity in patients with mild cognitive impairment or early Alzheimer's disease.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Rina De Guzman Zuniga, MD 301 Lippincott Dr Ste 410, Marlton, NJ 08053-4197 Ph: (856) 355-0340 | Rina De Guzman Zuniga, MD 141 Route 70 E Ste E, Marlton, NJ 08053-1855 Ph: (856) 985-7373 |
News Archive
Most healthy cells rely on a complicated process to produce the fuel ATP. Knowing how ATP is produced by the cell's energy storehouse - the mitochondria - is important for understanding a cell's normal state, as well as what happens when things go wrong, for example in cancer, cardiovascular disease, neurodegeneration, and many rare disorders of the mitochondria.
In a first-time disclosure of IPN60090, a small-molecule inhibitor of the metabolic enzyme glutaminase (GLS1), researchers from The University of Texas MD Anderson Cancer Center's Therapeutics Discovery division and Ipsen Biopharmaceuticals reported the preclinical discovery and early-stage clinical development of this novel drug. IPN60090, now under investigation in a Phase I trial, may hold benefit for certain patients with lung and ovarian cancers.
BIND Biosciences, Inc. (BIND), a privately held biopharmaceutical company developing best in class therapeutics based on its proprietary targeted nanotechnology platform, announced today that it has secured a $12.4 Million Series C-1 financing. This financing included all of BIND's current investors (including Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension and DHK Investments) as well as a new venture investor, Endeavour Vision, and private investors.
Researchers at the University of Toronto and Unity Health Toronto have demonstrated that repeated listening to personally meaningful music induces beneficial brain plasticity in patients with mild cognitive impairment or early Alzheimer's disease.
› Verified 8 days ago
Dr. Mahbubur Siddique, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 90 Brick Rd Fl 3, Marlton, NJ 08053 Phone: 856-355-6000 Fax: 856-355-6731 | |
Dr. Abraham S. Horn, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 406 Lippincott Drive, Suite E, Marlton, NJ 08053 Phone: 856-983-1900 Fax: 856-983-1914 | |
Martin Karl Belsky, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 100 Brick Rd, Suite # 108, Marlton, NJ 08053 Phone: 856-810-7337 Fax: 856-810-7917 | |
James Nicholas Kimbaris, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 601 Route 73 N Ste 101, Marlton, NJ 08053 Phone: 856-237-8045 Fax: 856-237-8047 | |
Dr. Gerald M Braverman, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 306 Posterity Pl, Marlton, NJ 08053 Phone: 856-988-0114 | |
Stacey Rene Zavala, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 406 Lippincott Dr Ste E, Marlton, NJ 08053 Phone: 856-983-1900 Fax: 856-983-5110 |